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Abstract
Aim: Skeletal muscle nitric oxide–cyclic guanosine monophosphate (NO-cGMP) pathways are impaired in
Duchenne and Becker muscular dystrophy partly because of reduced nNOSl and soluble guanylate cyclase
(GC) activity. However, GC function and the consequences of reduced GC activity in skeletal muscle are
unknown. In this study, we explore the functions of GC and NO-cGMP signaling in skeletal muscle.
Results: GC1, but not GC2, expression was higher in oxidative than glycolytic muscles. GC1 was found in a
complex with nNOSl and targeted to nNOS compartments at the Golgi complex and neuromuscular junction.
Baseline GC activity and GC agonist responsiveness was reduced in the absence of nNOS. Structural analyses
revealed aberrant microtubule directionality in GC1-/- muscle. Functional analyses of GC1-/- muscles revealed
reduced fatigue resistance and postexercise force recovery that were not due to shifts in type IIA–IIX fiber
balance. Force deficits in GC1-/- muscles were also not driven by defects in resting mitochondrial adenosine
triphosphate (ATP) synthesis. However, increasing muscle cGMP with sildenafil decreased ATP synthesis
efficiency and capacity, without impacting mitochondrial content or ultrastructure.
Innovation: GC may represent a new target for alleviating muscle fatigue and that NO-cGMP signaling may
play important roles in muscle structure, contractility, and bioenergetics.
Conclusions: These findings suggest that GC activity is nNOS dependent and that muscle-specific control of
GC expression and differential GC targeting may facilitate NO-cGMP signaling diversity. They suggest that
nNOS regulates muscle fiber type, microtubule organization, fatigability, and postexercise force recovery partly
through GC1 and suggest that NO-cGMP pathways may modulate mitochondrial ATP synthesis efficiency.
Antioxid. Redox Signal. 26, 966–985.
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Introduction
Neuronal nitric oxide synthase (nNOS) splice vari-ants, mu (nNOSl) and beta (nNOSb), synthesize the
majority of NO in skeletal muscle. We reported that nNOSl
and nNOSb-deficient (nNOSl/b-/-) muscles exhibit impaired
hypertrophic growth, severe weakness, exaggerated fatigue,
poor force recovery after exercise, and qualitative defects in
subsarcolemmal microtubule cytoskeleton organization (57).
nNOSl-/- muscles show a substantial increase in type IIX
fibers, while nNOSl/b-/- muscles show increased type IIB
fibers content at the expense of type IIA fibers (54, 56, 57).
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The specific mechanisms by which nNOS enzymes regulate
hypertrophy, fiber type, strength, fatigue resistance, and mi-
crotubule organization remain to be deciphered.
Four candidate mechanisms exist that may enable nNOS to
regulate multiple physiological processes, sometimes si-
multaneously in skeletal muscle. The first mechanism is
muscle-specific control of nNOS expression and activity
where glycolytic muscles can have higher nNOSl expression
and activity than oxidative muscles (41). Note that glycolytic
muscles exert fast contractions, fatigue rapidly, and are re-
quired for tasks involving strength and speed. Conversely,
oxidative muscles exhibit slow contraction speeds, high re-
sistance to fatigue, and are rich in mitochondria and capil-
laries. Oxidative muscles are important for maintaining
posture and tasks involving endurance (8). The second
mechanism is the dynamic activity-dependent control of
nNOSl localization (38, 71). The third mechanism is dif-
ferential nNOS isozyme sorting to create spatially and
functionally distinct nNOS splice variant compartments at
the sarcolemma, Golgi complex, neuromuscular junction,
and sarcoplasmic reticulum (2, 21, 41, 54, 57, 72). The fourth
mechanism is the choice of target or effector for NO.
Soluble guanylate cyclase (GC) is a direct physiological
target of NO (26). GC exists as two heterodimeric isoforms,
GC1 and GC2, which comprise a1b1 and a2b1 GC subunits,
respectively. Under resting conditions, GC synthesizes cyclic
guanosine monophosphate (cGMP) at low rates; however,
under activating conditions, additional NO binds GC sub-
stantially increasing cGMP synthesis (19). cGMP then acti-
vates proteins such as phosphodiesterase 5 (PDE5) and
cGMP-activated protein kinase (PKG). Little is known about
GC function in skeletal muscle, and it remains unknown
which functions of nNOS are mediated by GC. However,
expression of both GC1 and GC2 has been reported in skel-
etal muscle tissues, but reports conflict concerning GC1 lo-
calization at the sarcolemma (23, 28). In addition, current
evidence suggests that GC1, nNOSl, and PKG all localize to
the neuromuscular junction (2, 16, 23).
Mitochondria represent another important target of NO-
cGMP signaling. In skeletal muscle, NO is required for
normal mitochondrial integrity and NO-cGMP signaling may
regulate mitochondrial biogenesis, fission, and respiration in
muscle cells (17, 18, 43, 52, 53, 57). Supraphysiological PKG
overexpression drives the biogenesis of giant mitochondria
in vivo (49). However, it remains unknown if NO-cGMP
signaling controls biogenesis under more physiological
conditions. In addition, it is not known if GC1 regulates
skeletal muscle mitochondrial function or content.
NO-cGMP signaling can be terminated by PDE5 (25).
PDE5 catabolizes a small fraction of total cGMP in skeletal
muscle and its functions in skeletal muscle cells are poorly
defined (9). However, PDE5 does not appear to regulate
skeletal muscle strength and fatigue resistance (54, 60). In the
dystrophin-deficient skeletal muscles of Duchenne and
Becker muscular dystrophy (DBMD) patients and mdx mouse
model of Duchenne muscular dystrophy (DMD), PDE5 plays
clinically relevant roles in vasomodulation and fibrosis (6, 40,
47, 50, 55, 60). Inhibition of PDE5 with sildenafil partially
restores defective NO-GC-cGMP signaling, thereby improv-
ing blood delivery and reducing fibrosis in dystrophic muscle
(10, 13–15). Clinical testing is ongoing to evaluate PDE5 in-
hibition as a DBMD therapy. These findings underscore the
translational importance of deciphering skeletal muscle GC
and PDE5 function to clarify the role of impaired NO-cGMP
signaling in DBMD disease pathogenesis.
In the present study, we explore NO-GC1-cGMP signaling
in skeletal muscle using nNOS-/-, GC1-/- mice, and the
PDE5 inhibitor, sildenafil. We find that unlike nNOSl, GC1
expression was highest in oxidative muscles and that GC1
was targeted to nNOS compartments at the Golgi complex
and neuromuscular junction. Like nNOS-/- muscles, GC1-/-
muscles fatigued more rapidly, exhibited poor force recovery
after fatiguing exercise, and showed defects in microtu-
bule assembly and shifts in type II fiber composition. These
data suggested that nNOS regulates muscle contractility,
fiber type, and microtubule assembly partly through GC1-
dependent mechanisms. Reduced cGMP synthesis in GC1-/-
muscles had no impact on mitochondria. However, increasing
cGMP with sildenafil decreased the efficiency and capacity of
mitochondrial adenosine triphosphate (ATP) synthesis, with-
out impacting mitochondrial content or ultrastructure. These
data provide the first evidence for PDE5 as a novel modulator
of mitochondrial oxidative phosphorylation and a novel role
for NO-cGMP signaling in skeletal muscle bioenergetics.
Results
nNOS activity and expression were reported to be higher in
glycolytic than oxidative skeletal muscles; therefore, we
hypothesized that GC expression may also differ between
muscles (41). We found that the a1GC and b1GC subunits of
GC1 were expressed at a higher level in oxidative soleus and
diaphragm muscles compared with more glycolytic gastroc-
nemius and tibialis anterior (TA) muscles (Fig. 1A, B). In
contrast, expression of the a2GC subunit of GC2 did not
differ between muscles (Fig. 1C). These differences in GC
enzyme expression between skeletal muscle types suggest
greater cGMP synthesis capacity in oxidative muscles and
potential muscle-specific differences in GC enzyme function
and NO-cGMP signal propagation.
Another important characteristic of skeletal muscle NO
signaling is that it is facilitated by nNOS isoform sorting. To
test if GC enzyme sorting could also serve as a mechanism to
enable nNOS signaling diversity (by restricting GC NO re-
ceptor localization), we investigated GC targeting to known
nNOS compartments. The b1GC subunit colocalized with the
Innovation
Skeletal muscle nitric oxide–cyclic guanosine mono-
phosphate (NO-cGMP) pathways are therapeutic targets
in dystrophinopathies. However, the functions of key
members of this pathway, soluble guanylate cyclase (GC)
and phosphodiesterase 5 (PDE5), remain unknown. We
show evidence that NO-cGMP signaling may differ be-
tween skeletal muscles and be facilitated by differential
targeting of GC isoforms. We also provide evidence that
GC1 may play important roles in muscle fatigue, plastic-
ity, and microtubule organization. These findings suggest
GC1 as a new target for alleviating muscle fatigue. We
show that cGMP enhancement with sildenafil reduces
mitochondrial adenosine triphosphate synthesis efficiency
and capacity, suggesting a new role for PDE5 in mito-
chondrial bioenergetics.
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FIG. 1. GC expression differs between oxidative and glycolytic skeletal muscles and GC localizes to membranes of
the cis-Golgi complex. (A) Quantitation of Western blots of a1GC subunit (GC1) expression in WT glycolytic (gastroc-
nemius and tibialis anterior) and oxidative (soleus and diaphragm) skeletal muscles from 3-month-old mice (B) Quantitation
of Western blots of b1GC subunit expression in gas, TA, sol, and dia skeletal muscles from 3-month-old WT mice. (C)
Quantitation of Western blots of a2GC subunit (GC2) expression in glycolytic and oxidative skeletal muscles from 2-
month-old WT mice. In (A–C), expression was normalized to mean gastrocnemius GC subunit expression. n= 7 for all
groups. **p < 0.01, ***p < 0.001, and ****p < 0.0001 by one-way ANOVA with Tukey’s multiple comparison test. (D)
Representative confocal micrographs showing colocalization (right panel) of the cis-Golgi complex marker, GM130 (left
panel), and the b1GC subunit (middle panel) in a WT gastrocnemius myofiber. (E) Representative confocal micrographs of
a1GC-/- gastrocnemius myofiber showing normal GM130 labeling (left panel), but reduced cis-Golgi b1GC labeling
(middle panel). For (D, E), insets show a magnified view of Golgi labeling with n ‡ 6 for WT and a1GC-/- groups. (F)
Representative Western blots of a1GC and b1GC expression in gas, TA, sol, and dia from WT and a1GC-/- mice. (G)
Quantitation of Western blots of b1GC expression in a1GC-/- muscles. b1GC expression is expressed as mean percentage
of WT. For (F, G), n= 7 for both groups. ****p < 0.0001 by Student’s unpaired t-test comparison of mean b1GC expression
between WT and a1GC-/- muscles. GC, soluble guanylate cyclase; Gas, gastrocnemius; TA, tibialis anterior; Sol, soleus;
Dia, diaphragm; WT, wild-type. To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars
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cis-Golgi marker, GM130, in wild-type muscles where
nNOSb was found (Fig. 1D) (57). b1GC subunit also local-
ized to striations seen previously in cardiac muscle cells (12).
Golgi-associated b1GC was reduced in GC1-/- muscles,
likely due to reductions in b1GC expression; however, these
data nonetheless support an association of GC1 with the cis-
Golgi (Fig. 1E). Western blotting showed that loss of a1GC
reduced b1GC expression by 60% (Fig. 1F, G). Similarly, the
a1GC subunit also localized to the cis-Golgi and to other
structures, including striations and neighboring blood vessels
(Fig. 2E). Together, these data provide evidence that NO-
sensitive GC1 may act as an effector for nNOSb at the cis-
Golgi complex in skeletal muscle cells.
In contrast, the a2GC subunit of GC2 did not localize to the
Golgi, but to striations (Fig. 2A). Blood vessels were also
labeled with a1GC, a2GC, and b1GC subunit antibodies,
indicating that GC1 and GC2 are expressed in the mus-
cle vasculature (Fig. 2A, B, E). Importantly, b1GC was not
expressed at the sarcolemma (Fig. 2C), but at blood ves-
sels (puncta), and colocalized with acetylcholine recep-
tors (AchR) on the postsynaptic muscle membranes at the
neuromuscular junction (Fig. 2D). We were unable to
FIG. 2. GC is targeted to the neuro-
muscular synapse in muscle cells and
expressed in muscle-associated micro-
vasculature. (A) Representative confocal
micrographs showing that a2GC subunit
is not localized to the cis-Golgi complex
marked by GM130, but is expressed
in blood vessels closely associated
with muscle cells in the tibialis anterior.
Striated staining was also observed po-
tentially representing another GC2 com-
partment. (B) Representative confocal
micrographs showing that b1GC subunit
localizes to the cis-Golgi complex
marked by GM130 in myofibers and
to muscle-associated blood vessels.
(C) Representative confocal micrographs
of a transverse section of gastrocnemius
muscles coimmunolabeled with a-
bungarotoxin to identify postsynaptic
AchRs of the neuromuscular junction
(left panel) and anti-b1GC antibodies
(middle panel). b1GC was enriched at the
neuromuscular junction (right panel) and
in blood vessels, but did not localize to
the sarcolemma. (D) Representative high-
magnification confocal micrographs
showing an en face view of the neuro-
muscular junction labeled with AchR (left
panel) from a gastrocnemius myofiber.
b1GC (middle panel) colocalized with
AchR (right panel), indicating targeting
of GC to the neuromuscular synapse. (E)
Representative confocal micrographs
showing that a1GC subunit is localized to
the cis-Golgi complex marked by GM130
and to striations and blood vessels closely
associated with individual muscle fibers
in the tibialis anterior. For all groups,
n ‡ 3. AchR, acetylcholine receptor. To
see this illustration in color, the reader is
referred to the web version of this article
at www.liebertpub.com/ars
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demonstrate a1GC or a2GC colocalization with AchR for
reasons that are unclear (not shown). Thus, GC is situated
close to nNOSl at postsynaptic, but not sarcolemmal,
membranes. AchR distribution was unaffected by the loss of
nNOS (Supplementary Fig. S1G; Supplementary Data are
available online at www.liebertpub.com/ars). Together, these
data indicate that GC is targeted to a subset of nNOS com-
partments, supporting the control of GC sorting as a mech-
anism to generate nNOS signaling diversity and suggesting a
dependence of GC function on nNOS.
To test the dependence of cGMP synthesis by GC on nNOS,
we investigated GC activity at baseline and in response to
agonists in nNOS-/- muscles. Basal GC activity was reduced
to a similar extent in nNOS-/- and GC1-/- TA muscles relative
to wild-type controls (Fig. 3A). However, baseline GC activity
was significantly reduced in GC1-/-, but not nNOS-/-, soleus
muscles (Fig. 3C). Differences in basal GC activity between
nNOS-/- TA and soleus muscles may be due to greater vas-
cularization of the soleus with higher nonmuscle resting GC
activity. These data indicate that GC1 is a significant cGMP
source in both resting TA and soleus muscles and that baseline
GC1 activity is nNOS dependent in TA muscles.
We then tested the nNOS dependence of GC activation by
distinct agonists, including the NO donor, DETANO, the GC
activator, BAY 58-2667 (BAY 58), and the GC stimulator,
BAY 41-2272 (BAY 41) (22, 24, 70). GC activation by
DETANO, BAY 58, or BAY 41 was decreased in nNOS-/-
TA muscles (Fig. 3A). Indeed, GC activity was not signifi-
cantly different between agonist-treated nNOS-/- and GC1-/-
TA muscles. Remarkably, these data suggest that nNOS-
dependent activation of GC cannot be fully mimicked by
addition of exogenous NO and that BAY 41 may not be fully
NO independent in glycolytic skeletal muscle. Similar trends
in GC agonist responsiveness were seen in the soleus, except
that BAY 41 stimulated GC to wild-type levels (Fig. 3C).
Normalization of DETANO, BAY 58, and BAY 41 agonist-
induced GC activity to baseline activity in the TA and soleus
showed similar trends reflecting the strong nNOS depen-
dence of GC activation (Fig. 3B, D).
We then tested decreased GC subunit expression as a
mechanism for reducing GC activity and agonist respon-
siveness. Western blotting revealed that a1, b1, and a2GC
subunit expression was not decreased in nNOS-/- gastroc-
nemius, TA, soleus, or diaphragm muscles (Fig. 3E–G and
Supplementary Fig. S1A). On the contrary, a1 and b1GC
exhibited a compensatory increase in both gastrocnemius and
diaphragm muscles (Fig. 3E, F). Therefore, reduced GC ac-
tivity in nNOS-/- muscles was not caused by decreased GC
subunit expression. Importantly, these data collectively
suggest that GC activity is strongly nNOS dependent and that
GC1 inhibition may contribute to skeletal muscle dysfunction
in nNOS-/- mice.
To further understand the regulation of sGC activity by
nNOS, we investigated whether sGC and nNOS could exist in
a cytosolic complex by immunoprecipitation analysis. The
anti-a1GC antibody could immunoprecipitate nNOSl in WT,
but not nNOS-/-, diaphragm muscles (Fig. 3H). Similar re-
sults were observed in TA muscles (not shown). The converse
immunoprecipitation was unsuccessful. These findings sug-
gest that a1b1 sGC and nNOSl exist in a complex together in
the cytoplasm, which may facilitate the regulation of sGC by
nNOS.
Given that loss of nNOS impaired baseline GC activity and
agonist responsiveness, we investigated if the converse was
possible that loss of GC may reduce nNOS activity. Because
it is not possible to specifically measure nNOS activity alone
in vivo, we evaluated the fraction of active serine1446
phosphorylated nNOSl, the primary enzymatic NO source in
muscle (34, 61). Loss of GC1 decreased the fraction of active
serine1446 phosphorylated nNOSl by 40% (Supplementary
Fig. S1B). These findings suggest a negative feedback loop
between nNOSl and GC1, whereby loss of GC1 activity
attenuates upstream nNOSl activity.
The dependence of GC activity on nNOS suggested that
inhibition of GC1 could contribute to muscle dysfunction in
nNOS-/- mice; therefore, we investigated possible functions
of nNOS that could be mediated by GC1. Male and female
nNOS-/- mice were previously shown to exhibit stunted
growth (57). However, growth of male and female GC1-/-
mice was similar to wild type, suggesting that growth defects
in nNOS-/- mice were not due to impaired GC1 activity
(Fig. 4A) (30, 57). Dual-energy X-ray absorptiometry indi-
cated decreased body fat in male GC1-/- mice (Fig. 4B),
while bone mineral density was unaffected (Fig. 4C).
nNOS-/- TA masses were reported to be very low due to
reduced muscle cell size marked by reduced feret diameter
and cross-sectional area (57). However, GC-/- mice ex-
hibited normal absolute TA masses and body weight nor-
malized TA masses (Fig. 4D, E, respectively). These findings
suggest that a global increase in male skeletal muscle mass
was not solely responsible for the reduction in body fat per-
centage. Consistent with normal muscle growth, GC1-/-
muscle cells were of normal size and exhibited no evidence of
myopathy, dystrophy, or atrophy (Fig. 4F and Supplementary
Fig. S1C, D). Accordingly, central nucleation, a biomarker of
muscle cell degeneration/regeneration, was also normal in
GC1-/- muscle (Fig. 4G). Feret diameters and cross-sectional
areas of TA muscle cells in GC-/- mice were similar to
controls, providing further evidence of normal GC-/- muscle
growth (Fig. 4H, I, respectively). Importantly, these data
suggest that GC1 is dispensable for normal skeletal muscle
growth and that impaired hypertrophic growth in nNOS-/-
mice was not due to inhibition of GC1 activity (57).
In addition to impairing muscle growth, nNOS-/- deficiency
was shown to qualitatively disrupt the subsarcolemmal mi-
crotubule lattice (Fig. 5A, B) (57). To quantitate the impact of
nNOS deficiency on microtubules, subsarcolemmal micro-
tubule lattice directionality was analyzed using custom-built
texture detection (TedT) software (Fig. 5C–E) (44). Loss of
nNOS quantitatively disrupted subsarcolemmal microtubule
organization (Fig. 5C). General microtubule directionality
(D) was reduced by 50% in nNOS-/- TA muscle, reflecting
impaired microtubule alignment (Fig. 5D). nNOS deficiency
reduced the number of transverse microtubules oriented at 90o
to the myofiber long axis (Fig. 5C). Accordingly, vertical di-
rectionality (Dv) was reduced by 84%, suggesting extreme
disarray of transverse microtubules (Fig. 5E). Loss of direc-
tionality was partly attributable to a 41% reduction in sub-
sarcolemmal microtubule density in nNOS-/- muscle (Fig. 5F).
To test if impaired subsarcolemmal microtubule organi-
zation in nNOS-/- muscles could be due to GC1 inhibition,
we determined microtubule directionality and density in
GC1-/- TA muscles. Confocal microscopic analyses showed
that the subsarcolemmal microtubule lattice was qualitatively
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FIG. 3. Resting GC activity and responsiveness to DETANO, BAY 58-2667, and BAY 41-2722 agonists are nNOS
dependent. (A) cGMP synthesis by GC at baseline and in response to NO donor, DETANO, the GC activator, BAY 58-
2667, and GC stimulator, BAY 41-2722, agonists in 2-month-old glycolytic TA muscles from WT, nNOS-/-, and a1GC-/-
mice now referred to as GC1-/- mice. (B) Fold increase in TA muscle GC activity compared with baseline. (C) GC activity
at baseline and in response to DETANO, BAY 58-2667, and BAY 41-2722 in 2-month-old oxidative soleus muscles from
WT, nNOS-/-, and GC1-/- mice. (D) Fold increase in soleus GC activity compared with baseline. (E) Quantitation of
Western blots evaluating a1GC expression in nNOS-/- glycolytic (gastrocnemius and TA) and oxidative (soleus and
diaphragm muscles). a1GC subunit expression in nNOS-/- muscles is expressed as percent of WT. (F) Western blot-based
quantitation of b1GC subunit expression in nNOS-/- muscles. b1GC expression is expressed as percent of WT. (G)
Quantitation of Western blots of a2GC subunit expression in nNOS-/- muscles. a2GC expression is expressed as percent of
WT. For (A–G), n = 8 for all groups. For (A–D), *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by one-way
ANOVA with Tukey’s multiple comparison test. For (E–G), *p < 0.05, **p < 0.01, and ****p < 0.0001 by Student’s un-
paired t-test comparison of mean b1GC expression between WT and nNOS-/- muscles. (H) Representative blots of
immunoprecipitation analyses showing that a1GC can immunoprecipitate nNOSl from WT, but not nNOS-/- diaphragm
muscle. n = 4.
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FIG. 4. GC1-/- mice exhibit sex-specific reductions in body fat and normal skeletal muscle cell hypertrophy. (A)
Body weights of male and female WT and GC1-/- mice. (B) Body fat percentage in male and female WT and GC1-/- mice
measured by DEXA. (C) DEXA measurement of bone mineral density in male and female WT and GC1-/- mice. (D) TA
muscle mass in WT and GC1-/- mice. (E) TA muscle mass normalized to body mass. (A–E), n = 8–10 for all groups. (F)
Representative bright-field micrographs of hematoxylin and eosin-stained TA muscles from male WT and GC1-/- mice.
n ‡ 6. (G) The percentage of centrally nucleated muscle fibers in WT and GC1-/- TA muscles. n = 8 for WT and 9 for GC-/-
groups. (H) Feret diameters of type IIA, IIX, and IIB-positive TA muscle cells in male and female WT and GC1-/- mice. (I)
Cross-sectional areas of type IIA, IIX, and IIB fibers in TA muscles from male and female WT and GC1-/- mice. (H, I),
n = 5 for all groups. For (A–E), (H, I), *p < 0.05, and ****p< 0.0001 from regular two-way ANOVA using sex and genotype
as variables and Tukey’s post hoc test. DEXA, dual-energy X-ray absorptiometry.
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FIG. 5. nNOS regulates subsarcolemmal microtubule lattice organization through a GC1-cGMP-dependent
mechanism. (A) Representative low-magnification confocal micrographs of the subsarcolemmal microtubule cytoskeleton
immunolabeled with FITC-conjugated anti-a-tubulin antibody in TA myofibers from WT, GC1-/-, and nNOS-/- mice. (B)
High-magnification versions of regions within the confocal micrographs in (A). (C) Histogram of subsarcolemmal mi-
crotubule general directionality in TA myofibers from WT, GC1-/-, and nNOS-/- mice. (D) Subsarcolemmal general
microtubule directionality scores in WT, GC1-/-, and nNOS-/- TA muscles. (E) Quantitation of vertical (microtubules
orthogonal to the myofiber long axis) microtubule directionality (Dv) in WT, GC1
-/-, and nNOS-/- TA myofibers. (F)
Quantitation of subsarcolemmal microtubule densities in TA myofibers from WT, GC1-/-, and nNOS-/- mice. (A–F), n = 3–
4 for all groups. For (C), ###p< 0.001; ####p < 0.0001 for WT versus nNOS-/-; and *p < 0.05 for WT versus GC-/- from
regular two-way ANOVA using orientation and genotype as variables with Tukey’s multiple comparison test. For (D–F),
*p < 0.05, **p< 0.01, ***p < 0.001, and ****p < 0.0001 by one-way ANOVA with Tukey’s multiple comparison test.
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FIG. 6. GC1 is indispensable for normal skeletal muscle fatigue resistance. The isometric tetanic contractile properties
of TA muscles in male and female WT and GC1-/- mice in situ. n = 9 for male groups, n = 10 and 7 for female WT and
GC1-/- groups, respectively. (A) Maximal tetanic isometric force output. (B) Specific force output. n = 19 for WT and 16 for
GC1-/- groups. (C) Normalized force–stimulation frequency relationship in WT and GC1-/- TA muscles. n= 18 per
group. (D) Contraction-induced fatigue resistance. n = 39 and 34 for WT and GC1-/- groups, respectively. (E) Fiber
composition in TA muscles from male and female WT and GC1-/- mice. n= 7 and 6 for male and female groups,
respectively. Isometric twitch contractile properties of TA muscles from WT and GC1-/- male and female mice. (F)
Maximum isometric twitch force output, (G) specific isometric twitch force output, (H) time to maximum isometric twitch
force, and (I) time taken for muscle force to return to half maximum twitch force (½ relaxation time) in WT and GC1-/- TA
muscles. For (F–I), n = 9 male WT groups. n = 10 and 7 for female WT and GC1-/- groups, respectively. (A, D, E) *p < 0.05;
**p < 0.01; and ***p< 0.001 from regular two-way ANOVA using sex and genotype (A, E) or genotype and time (D) or as
variables with Tukey’s multiple comparison test.
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disrupted in GC1-/- muscles (Fig. 5A, B). This was con-
firmed by quantitative image analysis, which showed that
GC1 deficiency disrupted microtubule organization (general
directionality) to a degree intermediate between wild-type
and nNOS-/- muscles (Fig. 5C, D). This suggests why
microtubule-scaffolded Golgi complex localization was rel-
atively normal in GC-/-, but not in nNOS-/-, muscles, as
previously reported (Fig. 1E) (57). In addition, microtubules
aligned at 90o to the long axis of the muscle fiber were
similarly disrupted in GC-/- and nNOS-/- muscles indicated
by decreased vertical directionality scores (Fig. 5E). Unlike
loss of nNOS, GC1 deficiency did not significantly reduce
microtubule density, suggesting a primary role for GC1 in
microtubule orientation (Fig. 5F). Together with the nNOS-
dependent of sGC activity, these data suggest that GC1-
dependent nNOS signaling may play a role in regulating
subsarcolemmal microtubule cytoskeleton organization in
skeletal muscle cells.
We next explored the consequences of GC1 deficiency on
muscle contractile performance by stimulating the TA mus-
cle to contract in situ in anesthetized mice through electrical
activation of the peroneal nerve. nNOS-/- TA muscles ex-
hibit severe reductions in maximal tetanic force, specific
force, and fatigue resistance (57). Therefore, given dimin-
ished GC1 activity in nNOS-/- muscles, we tested if GC1
inhibition could recapitulate the pronounced weakness of
nNOS-/- mice. Maximum tetanic force output was modestly
reduced in male, but not female, GC1-/- muscle (Fig. 6A).
However, specific force output from male and female GC1-/-
muscles was normal (Fig. 6B and Supplementary Fig. S2A).
These findings argue that GC1 is dispensable for muscle
strength and that muscle weakness in nNOS-/- mice was not
due to GC1 inhibition.
The neuromuscular junction localization of GC suggested
a role in motor neuron–muscle communication (Fig. 2D);
therefore, we investigated force output at different peroneal
nerve stimulation frequencies (Fig. 6C). Normalized force–
frequency relationships were indistinguishable between
control and GC1-/- muscles consistent with normal neuro-
muscular transmission (Fig. 6C and Supplementary Fig. S2B,
C). However, male and female GC1-/- TA muscles could not
sustain normal force output during repeated stimulation, in-
dicating poor fatigue resistance (Fig. 6D and Supplementary
Fig. S2D, E). Importantly, force output was depressed for
5 min after the fatigue period, indicating impaired postexer-
cise force recovery (Fig. 6D). Importantly, GC1-/- muscle
fatigue was not as severe as previously reported in nNOS-/-
mice, suggesting partial compensation by GC2 and/or that
nNOS regulates fatigue partly through a GC1-independent
mechanism (57). Nonetheless, these data suggest that NO-
GC1-cGMP signaling plays an important role in muscle fa-
tigue resistance and postexercise force recovery.
Skeletal muscle fatigue resistance depends partly on fiber-
type composition, with less fatigue-resistant muscles con-
taining a greater ratio of glycolytic to oxidative fiber types
(63). In addition, nNOS enzymes regulate type II fiber
composition (57). Therefore, we investigated whether GC1
could also play a role in type II fiber-type specification and
whether changes in fiber type could contribute to reduced
GC1-/- muscle fatigue resistance. Loss of GC1 significantly
decreased type IIA content by 41% in males, but increased it
by 42% in female TA muscles, although this increase did not
reach statistical significance (Fig. 6E). Male GC1-/- mice
showed a 42% increase in type IIX fibers; however, type IIX
content in GC1-/- females was unaffected (Fig. 6E). Type IIB
fiber composition was unaffected in GC1-/- muscles. To-
gether, these data indicate sex-specific regulation of oxida-
tive type II fiber composition by GC1. However, these
changes in fiber content are modest and unlikely to impact
muscle fatigue resistance or contractility. To gain additional
evidence that altered fiber composition did not impact con-
tractility, we determined the twitch properties of GC1-/- TA
muscles. Maximum twitch force, specific twitch force, time
to maximum twitch force, and time to reach ½ maximum
twitch force (½ relaxation time) were all unaffected in
GC1-/- muscles (Fig. 6F–I, respectively). Collectively these
data argue that altered type II fiber composition is not driving
the lowered muscle fatigue resistance of GC1-/- mice.
We next explored deficits in mitochondrial ATP synthesis
as a potential mechanism for the reduced muscle fatigue re-
sistance of GC1-/- mice. Because mitochondria are regulated
by NO and play a central role in skeletal muscle contractile
performance, we tested if mitochondrial oxidative phos-
phorylation was impacted by GC1 inhibition using in vivo
metabolic spectroscopy (5, 17, 18, 52, 53, 57, 67). Mi-
tochondrial ATP synthesis (Fig. 7A), which is directly pro-
portional to ATPase activity, and mitochondrial O2
consumption (Fig. 7B) were unaffected in resting GC1-/-
skeletal muscles. Accordingly, the P/O coupling ratio, an
index of how tightly ATP generation is coupled to O2 con-
sumption, was similar between controls and GC1-/- mice
(Fig. 7C). Maximal mitochondrial ATP synthesis capacity
(ATPmax, Fig. 7D) and phosphocreatine-to-ATP metabolite
ratios (PCr/ATP) were also unaffected in GC1-/- muscles
(Fig. 7E). Taken together, these data suggested that GC1 is
dispensable for mitochondrial ATP synthesis in resting
skeletal muscle.
We next investigated if preservation of mitochondrial ATP
synthesis in GC1-/- muscles was due to compensatory in-
creases in mitochondrial content. Western blotting showed
that expression of mitochondrial marker, VDAC1 (Fig. 7F),
and specific subunits of respiratory complexes I through V
(Fig. 7G) was unaffected in GC1-/- TA muscles (Fig. 7).
Similar results were observed in gastrocnemius and soleus
muscles (Supplementary Fig. S3A–D). Accordingly, ex-
pression of mitochondrial biogenesis regulator PGC1a
mRNA was similar between wild-type and GC1-/- muscles
(Fig. 7H). Together, these findings suggest that preservation
of mitochondrial ATP synthesis in GC1-/- mice was not due
to biogenesis. This loss-of-function approach also suggested
that cGMP synthesis by GC1 is dispensable for establishing
muscle mitochondrial content.
In skeletal muscle, cGMP synthesized by GC is broken
down by several phosphodiesterases, including cGMP-
activated and cGMP-specific PDE5 (9, 55, 60). To further
understand the regulation of muscle mitochondrial function
by cGMP, we used a gain-of-function approach to raise
skeletal muscle cGMP by treating wild-type mice with the
PDE5 inhibitor, sildenafil. Sildenafil treatment increased
skeletal muscle cGMP twofold (Fig. 8L) (60). Sildenafil re-
duced the P/O coupling ratio by 40%, indicating partial un-
coupling of O2 consumption from ATP generation (Fig. 8A).
The reduced P/O indicated very inefficient ATP synthesis
where mitochondria were oxidizing more fuel substrates to
FUNCTIONS OF NO-CGMP SIGNALING IN SKELETAL MUSCLE 975
generate the same amount of ATP. Reduced P/O was caused
by a decrease in ATP generation (Fig. 8B) and a concomitant
increase in O2 consumption (Fig. 8C). Inefficient ATP syn-
thesis predictably reduced maximal mitochondrial ATP
synthesis capacity (Fig. 8D). The reprogramming of mito-
chondrial oxidative phosphorylation was accompanied by a
decrease in the PCr/ATP ratio, driven by a reduction in
phosphocreatine (PCr) without impacting ATP levels
(Fig. 8E–G). PCr is an important buffer of ATP levels;
therefore, decreased PCr likely reflects an adaptive response
to preserve skeletal muscle ATP.
Given that increases in cGMP may drive mitochondrial
biogenesis in muscle cells, we tested if sildenafil-driven re-
ductions in ATP synthesis efficiency and capacity were
FIG. 7. GC1 is dispensable for resting skeletal muscle mitochondrial ATP synthesis and content. Mitochondrial ATP
generation and oxygen consumption in hind limb skeletal muscles of anesthetized WT and GC1-/- mice were simulta-
neously measured by in vivo 31P magnetic resonance and optical spectroscopy. (A) Mitochondrial ATP synthesis, which is
directly proportional to ATPase activity. (B) Mitochondrial oxygen consumption rate. (C) Mitochondrial ATP synthesis
efficiency as determined from the P/O coupling ratio, where P (ATP generation) is divided by oxygen consumption rate (O).
(D) Mitochondrial ATP synthesis capacity (ATPmax). (E) Phosphocreatine-to-ATP ratio. For (A–E), n= 9–10 for WT and
10–11 for GC1-/- groups, respectively. (F) Representative Western blot and densitometric quantitation of mitochondrial
marker VDAC1 expression in tibialis anterior muscles. n= 5 for WT and GC1-/- groups. (G) Representative Western blot
and densitometric quantitation of mitochondrial respiratory complex subunit expression in tibialis anterior muscles. (H)
Quantitation of PGC1a transcript expression by qPCR. For (G, H), n = 6 for WT and GC1-/- groups.
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accompanied by increased mitochondrial content using
Western blotting and quantitative electron microscopy-based
stereology (59). Expression of VDAC1 protein (Fig. 8H) and
specific subunits of respiratory complexes I through V
(Fig. 8I) were unaffected by sildenafil. In agreement, inter-
myofibrillar mitochondrial volume density (Fig. 8J) and
subsarcolemmal mitochondrial pool densities (Fig. 8K) were
similar between untreated and sildenafil-treated mice. In
addition to regulating biogenesis, NO-cGMP signaling may
also modulate mitochondrial size (17, 49). Therefore, we
evaluated the impact of increased cGMP on intermyofibrillar
and subsarcolemmal mitochondria ultrastructure by transmis-
sion electron microscopy (Supplementary Fig. S4). Sildenafil
had no impact on the gross morphology of intermyofibrillar or
subsarcolemmal mitochondria. Together, these data demon-
strate that increasing cGMP with sildenafil does not impact
muscle mitochondrial morphology or content. Importantly,
these findings provide new evidence that NO-cGMP pathways
regulated by PDE5 modulate skeletal muscle mitochondrial
ATP synthesis efficiency and capacity.
Discussion
While skeletal muscle nNOS-GC-cGMP signaling is se-
verely disrupted in DBMD, the functional consequences of
this disruption remain to be deciphered. We provide new
insights into the physiological functions of nNOS-GC-cGMP
signaling in skeletal muscle that may advance understanding
of how defects in this pathway promote disease pathogenesis
in DBMD. These insights are based on findings suggesting
that nNOS regulates muscle fatigue resistance, fiber specifi-
cation, and microtubule organization partly through GC1.
Our data also suggest muscle-specific differences in NO-
cGMP signaling supported by muscle-specific GC expres-
sion, GC activity, and GC agonist responsiveness. In addition,
our data provide an important new understanding of the reg-
ulation of GC activity by nNOS. We show that GC complexes
with nNOSl and associates with a subset of nNOS splice
variant compartments at the Golgi complex and neuromus-
cular junction, thus providing compelling evidence that dif-
ferential GC NO receptor targeting could facilitate NO-cGMP
signaling diversity in skeletal muscle. We advance under-
standing of the role of NO-cGMP signaling in mitochondrial
biology by showing that GC1 is dispensable for mitochondrial
content and function and that PDE5 is a negative regulator of
mitochondrial ATP synthesis efficiency. These findings sug-
gest a novel role for NO-cGMP-PDE5 signaling in skeletal
muscle mitochondrial bioenergetics.
Skeletal muscle-specific differences in nNOSl have been
reported with glycolytic muscles exhibiting higher nNOSl
expression and NOS activity than oxidative muscles (41). In
contrast, we find higher GC1 subunit expression in oxidative
compared with glycolytic muscles, suggesting a general re-
ciprocal relationship between nNOSl and GC1 in skeletal
muscles, that is, where nNOSl expression is highest, GC1 is
lowest. Higher relative GC1 expression in oxidative muscles
suggests not only a larger cGMP-synthesizing capacity but
also different responses to NO or cGMP modulation in these
muscle types. Supporting this possibility, treating the mdx
mouse model of DMD with sildenafil reduced dystrophic di-
aphragm muscle dysfunction with no impact on the TA (60).
Evidence of a close functional relationship between GC
and nNOS was supported by immunoprecipitation and sub-
cellular localization studies. a1GC and nNOSl were found
together in a cytoplasmic complex. Subcellular localization
analyses show that a1GC and b1GC associated with the cis-
Golgi complex. These data support an association of GC1
with the Golgi complex and suggest a role for NO-cGMP
signaling in the secretory or endocrine functions of skeletal
muscle. In addition, we found that unlike nNOSl, GC was
not localized to the sarcolemma, strengthening the case that
GC does not target to the sarcolemma (23, 28). We also found
that b1GC was enriched at the neuromuscular junction where
a1GC, nNOSl, and cGMP-dependent protein kinase locali-
zation were previously found (2, 16, 23). The functions of
NO-cGMP signaling at the neuromuscular synapse remain
unclear, but current evidence argues against a major role for
synaptic nNOS in AchR distribution or neuromuscular
transmission, but a possible role in agrin signaling (Supple-
mentary Fig. S1G) (1, 29). Thus, GC at the neuromuscular
junction may similarly be involved in agrin signaling. The
findings suggest that restricting the localization of GC to the
Golgi and neuromuscular junction could act as a mechanism
to generate functional differences in NO signal transduction
between these sites.
Additional evidence of a strong functional relationship
between GC and nNOS came from the findings that baseline
GC activity and GC responsiveness to NO donor, GC stim-
ulator, or GC activator agonists were nNOS dependent. Our
GC activity studies provided two noteworthy findings. First,
‰
FIG. 8. PDE5 negatively modulates skeletal muscle mitochondrial ATP synthesis efficiency and capacity without
impacting mitochondrial content. Skeletal muscle mitochondrial function was measured by in vivo spectroscopy in WT
mice treated with sildenafil for 3 months to increase cGMP. (A) Mitochondrial ATP synthesis efficiency as measured by the
P/O ratio. (B) Mitochondrial ATP synthesis rate (which is directly proportional to ATPase activity). (C) Mitochondrial
oxygen consumption rate. For (A–C), n = 7 and 6 for untreated WT and sildenafil-treated groups, respectively. (D) Mi-
tochondrial ATP synthesis capacity (ATPmax). n = 6 for both groups. (E) Phosphocreatine (PCr)-to-ATP metabolite ratio.
(F) Hind limb muscle phosphocreatine metabolite levels. (G) Hind limb muscle ATP levels. For (E–G), n = 7 and 6 for
untreated WT and sildenafil-treated groups, respectively. (H) Densitometric quantitation of Western blots of mitochondrial
marker VDAC1 protein expression in TA muscles. (I) Densitometric quantitation of Western blots of mitochondrial
respiratory complex subunit expression in TA muscles. For (H, I), n = 7 and 4 for untreated WT and sildenafil-treated
groups, respectively. (J) Quantitation of IFM volume density by electron microscopy-based stereology. (K) Electron
microscopy-based quantitation of subsarcolemmal mitochondria density in TA muscles. For ( J, K), n= 3–4 for each
group. (L) Immunoassay-based quantitation of cGMP concentrations in gastrocnemius muscles from WT and sildenafil-
treated mice (n = 7 and 6, respectively). *p < 0.05; **p < 0.01, by Student’s unpaired t-test comparison between untreated
and sildenafil-treated mice. IFM, intermyofibrillar mitochondria.
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the GC stimulator, BAY 41-2722, exhibited nNOS depen-
dence in the TA, which was surprising since its action is
widely considered NO independent. However, BAY 41-2722
did raise GC activity to wild-type levels in the soleus, sug-
gesting muscle-specific differences in BAY 41-2722 action.
Second, addition of DETANO could not activate GC to wild-
type levels in the absence of nNOS. This suggested the
remarkable possibility that exogenous NO could not fully
recapitulate the GC-activating function of endogenous
nNOS-derived NO for reasons that remain to be deciphered.
Our data suggest that nNOS is an important determinant of
GC activity, providing new mechanistic understanding of the
regulation of GC and supporting GC1 as an important target
of nNOS.
Analyses of muscle contractility in GC1-/- mice suggested
that GC1 was dispensable for muscle strength since specific
force was normal. This contrasts with early studies suggest-
ing that NO and cGMP promote skeletal muscle weakness
(41, 62). However, subsequent studies by the same group
made the opposite conclusion that NO in fact promotes
muscle contractility under physiological conditions (20, 32).
This reevaluation agrees with the majority of subsequent
studies, including the present one, which provides new evi-
dence that NO-cGMP signaling does not inhibit muscle
strength (54, 56).
While GC1 was dispensable for muscle strength, it was
essential for normal fatigue resistance and force recovery
after a fatiguing protocol. The extent of fatigue in GC-/-
muscles was comparable in magnitude with that in nNOSl-/-
muscles, but not in nNOSl/b-/- muscles, which exhibited
greater fatigability (57). This may suggest a more important
role for a2b1 sGC or NO-driven S-nitrosylation in skeletal
muscle fatigue resistance. In addition, it is important to note
that we cannot rule out potential compensatory increases in
a2b1 sGC resting activity or a2b1 sGC responsiveness to
agonist stimulation that occurs without a change in a2b1 sGC
expression. Nonetheless, our finding suggests that NO sig-
naling through GC1 is necessary for normal muscle fatigue
resistance under physiological conditions. This new insight
into the role of NO-GC-cGMP signaling in muscle fatigue
has potential implications for understanding poor fatigue
resistance and an exaggerated fatigue response to mild ex-
ercise in DBMD patients whose muscles have low nNOS and
GC activities (10, 13, 40). Our data suggest that defective
NO-GC signaling may exacerbate contraction-induced fa-
tigue and postexercise muscle weakness in DBMD patients.
While changes in fiber type were an unlikely cause of
muscle fatigue in GC1-/- mice, our data did provide new
evidence that NO plays an important role in regulating
muscle fiber type partly through a GC1-dependent mechanism.
GC1-/- males exhibited a type IIA to IIX fiber-type shift.
Importantly, nNOSl was shown to negatively regulate type
IIX fiber composition, although sex was not included as a
variable in this study (57). Thus, nNOSl may regulate muscle
type IIX fiber content through a sex-specific and GC1-
dependent mechanism. Taken together, these data suggest that
nNOS promotes muscle fatigue resistance partly through a
GC1-dependent, but fiber-type-independent, mechanism.
In addition to regulating fiber type, GC1 may also regulate
the organization of the subsarcolemmal microtubule cyto-
skeleton. GC1-/- muscles exhibited a qualitative and quan-
titative disruption of the microtubule lattice intermediate in
severity between wild-type and nNOS-/- muscle, consistent
with our report of a qualitative disruption of subsarcolemmal
microtubules in nNOS-/- muscles (57). Taken together, these
findings suggest that nNOS may regulate subsarcolemmal
microtubule organization, partly through GC1, and that NO-
cGMP signaling is an important regulator of the microtubule
cytoskeleton in skeletal muscle. This raises the question of
what the consequences of microtubule disruption might be.
Microtubules play firmly established roles in the scaffolding
and dynamics of organelles, including the Golgi complex and
mitochondria. Therefore, microtubule disorganization may
contribute to aberrant Golgi complex localization and mito-
chondrial morphology in nNOS-/- muscles (57). However,
Golgi localization was not impaired in GC1-/- muscles,
possibly because Golgi localization is more dependent on
longitudinal microtubules, which were better preserved in
GC1-/- than nNOS-/- muscles. Microtubule defects in
GC1-/- mice were also not associated with defects in mito-
chondrial ATP synthesis or content. However, microtubule
defects were associated with increased fatigability and im-
paired postexercise force recovery in both nNOS-/- and
GC1-/- muscles, as well as muscle weakness in nNOS-/-
muscles (57). So, NO-cGMP pathways may regulate mus-
cle contractile function, in part, through a microtubule-
dependent mechanism.
Microtubule defects were not associated with defects in
mitochondrial ATP synthesis or content in GC1-/- skeletal
muscle, indicating that cGMP synthesis by GC1 is dispens-
able for mitochondrial ATP synthesis and content in resting
muscle. However, blocking cGMP breakdown by PDE5 with
sildenafil reduced ATP synthesis efficiency, with mitochon-
dria consuming larger amounts of O2 and substrates (e.g.,
fatty acids and sugars) to generate ATP. While the mecha-
nisms underpinning reduced ATP synthesis efficiency remain
to be determined, proton and electron leaks from the electron
transport chain represent an attractive causal mechanism (3).
These findings support a novel role for PDE5 as a regulator of
ATP synthesis efficiency and skeletal muscle bioenergetics.
NO has been previously linked to skeletal muscle mito-
chondrial ATP synthesis efficiency in humans (42). Dietary
nitrate supplementation increased ATP synthesis efficiency
in healthy humans by reducing proton leak without impacting
biogenesis (42). In contrast, we find that increasing NO-
cGMP signaling decreased ATP synthesis efficiency in
healthy mice. However, both studies support a role for NO in
modulating ATP synthesis efficiency. One other interesting
result was that cGMP enhancement with sildenafil had no
impact on total, subsarcolemmal, or intermyofibrillar mito-
chondrial content. This argues against compensatory bio-
genesis in the face of decreased efficiency and contrasts with
reports showing that increases in NO or cGMP promote
biogenesis (18, 43, 52, 53). It is conceivable that PDE5 does
not regulate biogenesis in muscle or that sildenafil did not
produce a sufficient cGMP increase to induce biogenesis.
This is important because biogenesis may occur in response
to high or supraphysiological increases in NO-cGMP sig-
naling (49, 52, 53). Taken together, our data suggest that
NO-cGMP-PDE5 signaling modulates mitochondrial ATP
synthesis independently of mitochondrial content.
Strategies that partially uncouple skeletal muscle mito-
chondria to promote inefficiency represent an attractive an-
tiobesity therapy for humans because they increase energy
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expenditure and promote fat loss (33). Recent evidence
suggests that decreased NO-cGMP signaling in tissues, in-
cluding skeletal muscle, is a pathogenic feature of obesity
(31, 39, 48, 49, 51). Enhancing NO-cGMP signaling in mouse
models of diet-induced obesity with sildenafil, GC stimula-
tor, BAY 41-8543, or by PKGI overexpression protected
against high-fat diet-driven energy imbalance and insulin
resistance (4, 7, 35, 36, 48, 49, 51). However, the mechanisms
by which PDE5 inhibition protects against obesity remain
unclear (37, 48). Based on our data, it is tempting to speculate
that one novel mechanism by which PDE5 inhibition may
protect against obesity is through induction of inefficient
mitochondrial ATP synthesis in skeletal muscle, which




Mice lacking nNOS activity (nNOS-/-) were generated
by targeted deletion of exon 6 of the NOS1 gene and have
been described previously (30). Mice lacking active guany-
late cyclase 1 (GC1) were previously generated by targeted
deletion of exon 6 encoding part of the catalytic domain of
the a1 subunit of GC1 (11). GC1 mice express a truncated,
but catalytically inactive, GC1. All mice were on congenic
C57Bl backgrounds and age- and sex-matched adult lit-
termates were used unless otherwise stated. Mice harbor-
ing mutations in members of nNOS-NO-GC-cGMP signal
transduction pathways exhibit sex-specific cardiovascular,
motor, and reproductive phenotypes; therefore, sex was
considered as an experimental variable (11, 26, 30, 56, 69).
Where sex-specific differences were observed, male and fe-
male data are reported separately. If no difference between
sexes was observed, then the data were pooled. All experi-
mental procedures performed on mice were approved by
the Institutional Animal Care and Use Committees of the
University of Miami.
Sildenafil administration
The PDE5 inhibitor sildenafil dosing regimen has been
previously described where sildenafil citrate (Pfizer) was
administered in the drinking water ad libitum (400 mg/L) to
wild-type mice for 14 weeks starting after weaning (60).
Dual-energy X-ray absorptiometry densitometry
Body composition, including bone mineral density, and
body fat percentage of 4-month-old mice were determined by
dual-energy X-ray absorptiometry densitometry in Avertin-
anesthetized mice using a Lunar PIXImus Densitometer (GE
Medical Systems) according to the manufacturer’s instructions.
Immunofluorescence labeling and confocal
microscopy of myofibers
The methodology used to immunolabel single myofibers is
identical to that previously reported, except that confocal
images were captured with an Olympus FluoView FV1000
confocal microscope (58). Identical laser power, excitation,
and emission capture settings were used when comparing
b1GC localization between wild-type and GC1-/- muscles.
Primary antibodies used were a1GC (Sigma-Aldrich), b1GC
(Sigma-Aldrich), and a2GC (Thermo Scientific). FITC-
conjugated anti-a tubulin antibodies were used to label mi-
crotubules (Sigma-Aldrich; clone DM1A). Acetylcholine
receptors were labeled with Alexa 488-conjugated a-
bungarotoxin (Invitrogen).
Western immunoblotting
Skeletal muscles were homogenized in buffer (2% sodium
dodecyl sulfate, 50 mM Tris-HCl, pH 6.8) with protease and
phosphatase inhibitors (Roche). Thirty micrograms of protein
per sample was electrophoresed on 4–20% Mini-PROTEAN
TGX Stain-Free Precast Gels (Bio-Rad) and transferred to
polyvinylidene fluoride membranes (Millipore). Equiv-
alency of loading in gels and membranes was determined
using the stain-free detection system and a Bio-Rad Chemi-
Doc MP imager. Protein expression was normalized to total
transferred protein using Bio-Rad ImageLab 5.2.1 software.
Membranes were blocked with 5% (w/v) skim milk in Tris-
buffered saline with Tween-20 for 1 h at room temperature
and incubated with primary antibodies overnight at 4C.
Primary antibodies used were rabbit anti-VDAC1 (Sigma
Aldrich), rabbit pan anti-nNOS (Sigma-Aldrich), and rabbit
anti-phospho nNOS1412 (Abcam). ser1412 corresponds to
ser1446 in nNOSl due to the 34 amino acid l insert (68).
MitoProfile total OXPHOS antibody cocktail (Abcam) was
used to detect respiratory complex subunits NDUFB8
(Complex I or CI), SDHB (CII), UQCRC2 (CIII), MTCO1
(CIV), and ATP5A (CV). Primary antibodies were detected
with donkey horseradish peroxidase-conjugated secondary
antibodies ( Jackson ImmunoResearch Laboratories). Che-
miluminescence was visualized with SuperSignal West
Femto Maximum Sensitivity substrate (Thermo Fisher) on a
Biorad ChemiDoc MP imaging system.
Soluble guanylate cyclase activity
Soluble guanylate cyclase (GC) enzyme activity in skele-
tal muscles was measured as described (11). Briefly, muscles
were homogenized in buffer containing 50 mM Tris-HCl
(pH 7.6), 1 mM EDTA, 1 mM dithiothreitol, and 2 mM phe-
nylmethylsulfonyl fluoride. Extracts were centrifuged at
20,000 g for 20 min at 4C. Supernatants containing 50lg
protein were incubated for 10 min at 37C with 50 mM
Tris-HCl (pH 7.5), 4 mM MgCl2, 0.5 mM 1-methyl-3-
isobutylxanthine, 7.5 mM creatine phosphate, 0.2 mg/ml
creatine phosphokinase, 1 mM L-NAME, and 1 mM GTP
with or without 10lM of NO donor, DETANO, 100 lM sGC
activator, BAY 58-2667 (cinaciguat), or 1 mM of sGC stim-
ulator, BAY 41-2272 (22, 24, 70). BAY 58-2667 activates
GC only when it is oxidized (Fe3+) or in a heme-free state,
providing additive, but not synergistic, effects with NO,
which cannot activate GC in this state. Thus, BAY 58-2667
GC activator is an NO- and heme-independent agonist. BAY
41-2272 is an NO-independent allosteric GC stimulator that
binds the reduced (Fe2+) form of GC, making it sensitive to
low NO concentrations. BAY 41-2272 is considered an NO-
independent and heme-dependent GC agonist. The reaction
was terminated with 0.05 M HCl. cGMP was measured by
immunoassay (Cayman Chemical). sGC activity was ex-
pressed as picomoles of cGMP synthesized per milligram of
muscle protein per minute.
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Immunoprecipitation assays
Skeletal muscle tissues were lysed in buffer containing 1%
Nonidet P-40, 50 mM Tris-HCL, pH 7.4, 150 mM NaCl,
2 mM EGTA, 2 mM PMSF, and protease inhibitor cocktail
(Roche Applied Science). Immunoprecipitations were per-
formed using the Dynabeads Protein G immunoprecipita-
tion kit (Invitrogen) according to the manufacturer’s
instructions using an anti-a1 sGC (GC1) antibody (Sigma-
Aldrich). Bound protein was eluted in loading buffer con-
taining 1% SDS. Sample lysates were then analyzed by
Western blot using an anti-nNOS antibody (BD Biosciences).
Analyses of muscle histopathology, central nucleation,
fiber type, and myofiber area
Freshly isolated skeletal muscles were flash-frozen in
liquid nitrogen-cooled 2-methylbutane. Ten-micron-thick
cryosections cut from muscle mid-bellies were stained with
hematoxylin and eosin using standard methods. Muscles
were inspected for evidence of myopathy or dystrophy
marked by occurrence of central nucleation, increased fiber
size heterogeneity, and immune cell infiltration as described
(27, 57, 60). Immunofluorescent labeling of transverse
muscle cryosections was performed as previously described
(27). To discern shifts in fiber composition, muscle mid-belly
cryosections were immunolabeled with a cocktail of mono-
clonal antibodies against type I (clone BA-D5), type IIA
(clone SC-71), and type IIB (clone BF-F3) myosin heavy
chains (Developmental Studies Hybridoma Bank) as de-
scribed (57). Antimyosin antibodies were detected using
isotype-specific secondary antibodies: Alexa Fluor 350-
labeled donkey anti-mouse IgG2B (BA-D5), Alexa Fluor
594-labeled donkey anti-mouse IgG1 (SC-71), and Alexa
Fluor 488 donkey anti-mouse IgM (BF-F3). The incidence
(number of positive muscle cells divided by the total number
of muscle cells in the entire section) of type I, type IIA, and
type IIB myosin heavy chain-positive muscle cells was de-
termined manually. Unlabeled fibers were designated type
IIX. Feret diameters and cross-sectional areas of 300 type IIX
myofibers, 400 type IIB, and 100 type IIA myofibers, re-
presenting about a quarter of each myofiber fiber type, were
determined per mouse from spatially calibrated images using
ImageJ 1.46r software (64).
Automated bright-field and immunofluorescence
microscopy
For microscopic analyses of muscle morphology and fiber
type, images of entire muscle sections were obtained at
20 ·magnification with a DP80 digital camera (Olympus) in
combination with an automated capture and tiling system.
The system was run by CellSens software (Olympus) and
comprised an Olympus BX50 upright microscope fitted with
a Prior Scientific motorized x-y stage. Images of whole
muscle sections labeled with hematoxylin and eosin were
created by stitching individual color images captured se-
quentially together into a single composite image. For fluo-
rescent images obtained in fiber typing experiments,
individual images of Alexa 350, 488, and 594 fluorescence
emissions were captured sequentially, then automatically
stitched together to form a composite image of the entire
muscle cross section.
Gene expression analysis
PGC1a, Atrogin 1, and MuRF1 transcript expression lev-
els were determined by quantitative real-time PCR. Total
RNA was isolated from skeletal muscles using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions.
cDNAs were generated from 1lg of total RNA using the iS-
cript cDNA Synthesis Kit (Bio-Rad). Real-time PCR was
performed using the Sso Advanced Universal SYBR Green
Supermix (Bio-Rad) on CFX Connect Real-Time PCR detec-
tion system (Bio-Rad). Gene expression was normalized to the
Rps18 housekeeping gene and analyzed using the DDCT
method with Bio-Rad CFX Manager 3.1 software (45). Atrogin
1 forward and reverse primer sequences are 5¢-AAAGGG
CAGCTGGATTGGAA and 5¢-TGAGGGGAAA-GTGAGA
CGGA, respectively. MuRF1 forward and reverse primer se-
quences are 5¢-GTCTG-GAGGTCGTTTCCGTT and 5¢-AG
CAAGTAGGCACCTCACAC, respectively. PGC1a primers
were purchased from Biorad (qMmuCID0006032).
Quantitation of microtubule directionality and density
Microtubule directionality measurements were made using
texture detection (TedT) software (44). Confocal images re-
presenting either a single optical section or a maximum
projection of 1–3 sections containing the subsarcolemmal
microtubule cytoskeleton were captured. Images were auto-
matically contrasted and rotated using Adobe Photoshop
software so that the long axis of the myofiber ran from left to
right. Images were opened in (TedT) software, two peaks and
two valleys were selected, and then general directionality
scores (D), vertical directionality scores (DV), and direc-
tionality histograms (HD) were determined. Texture corre-
lation values for individual images were normalized and
plotted against microtubule orientation. Subsarcolemmal
microtubule densities in single myofibers were captured by
thresholding tubulin fluorescence at different gray values
from 8-bit grayscale images using ImageJ version 1.46r
software. The number of tubulin-positive pixels and total
number of pixels in the myofiber were determined using the
histogram algorithm in ImageJ. The fraction of tubulin-
positive pixels was normalized to the mean control value. For
all analyses, microtubules associated with nonmuscle cells
and myonuclei were excluded; 14–18 representative images
from at least three mice per group were analyzed.
In situ measurement of TA strength and fatigue
resistance
Tests of muscle contractile performance were performed
on the TA muscle in situ in anesthetized mice as described
(56). The contractile function of the TA muscle was mea-
sured using an in situ muscle test system (Aurora Scientific,
Inc.) Briefly, anesthetized mice were positioned on a heated
platform and the distal tendon of the TA was attached to the
lever arm of a servomotor. The TA muscle was activated by
peroneal nerve stimulation using needle electrodes and ad-
justed to an optimum length (Lo) to produce the maximum
tetanic force. Specific force was determined by normalizing
force output to muscle cross-sectional area (Lo · pennation
angle correction factor · density]/muscle mass). To test the
susceptibility of muscles to fatiguing stimulation, TA mus-
cles were subjected to fatigue protocol of 120 isometric
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tetanic stimulations (200 Hz) at 2-s intervals lasting 4 min.
Following the fatigue protocol, force output was determined
after 1, 3, and 5 min to monitor the muscle force recovery.
In vivo metabolic spectroscopy analysis
of mitochondrial ATP synthesis
These methods have been described in detail previously (59,
65, 67). Briefly, muscles of the lower hind limbs of anesthe-
tized mice were subject to a short bout of ischemia, and then
allowed to recover. Fluxes in muscle mitochondrial ATP
generation and O2 consumption were simultaneously mea-
sured during ischemia and recovery periods by 31P magnetic
resonance and optical spectroscopy, respectively (5, 67). These
fluxes were used to calculate the efficiency of mitochondrial
ATP synthesis (P/O coupling ratio) and maximal ATP syn-
thesis capacity. Mice were anesthetized with intraperitoneal
injections of 0.01 ml g-1 of 2.5% tribromoethanol (Sigma-
Aldrich), then strapped into a custom-built multimode probe
for 31P magnetic resonance and optical spectroscopy devel-
oped for a 7T vertical bore spectrometer (Varian). Following
signal optimization, 31P and optical spectra were collected
concurrently during an initial resting period (*2 min), then
during hind limb ischemia (*11 min) and recovery (*7 min)
periods. The resulting 31P and optical spectra were processed
as described previously and were used to derive resting rates of
mitochondrial ATP production (ATPase, P) and O2 con-
sumption (O), efficiency of coupling of oxidation to phos-
phorylation (P/O), and the maximum rate of oxidative
phosphorylation (ATPmax) (59, 65, 66). ATP, PCr, hemo-
globin, and myoglobin concentrations were quantitated from
pooled hind limb skeletal muscles as described previously (46).
Quantitation of mitochondrial content by transmission
electron microscopy
Mitochondrial ultrastructure, subsarcolemmal, and inter-
myofibrillar mitochondrial pool densities were determined in
TA muscles by transmission electron microscopy analysis as
described previously (57, 59).
cGMP quantitation
Acetylated cGMP levels in skeletal muscle lysates were
quantitated by Detect X Direct Cyclic GMP immunoassay
according to the manufacturer’s instructions (Arbor Assays).
Optical densities were read at 450 nm with a Synergy H1
microplate reader using Gen5 Imager Software (BioTek In-
struments, Inc.) cGMP was normalized to protein concen-
trations determined with a Pierce BCA Protein Assay Kit
with BSA as standard (Thermo Fisher Scientific). All assays
were in duplicate, and cGMP concentrations expressed as
picomoles per milligram of protein.
Statistical analyses
All values are reported as mean – standard error of the
mean. Protein and mRNA expression data were normalized by
dividing all values by the mean of the wild-type control
group. The specific statistical tests used to determine signifi-
cant differences between group means are included in figure
legends. Statistical calculations were performed using Prism v
6.07 (Graphpad Software, Inc.), with p values <0.05 consid-
ered significant.
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Abbreviations Used
a1GC¼ a1 soluble guanylate cyclase subunit
a2GC¼ a2 soluble guanylate cyclase subunit
b1GC¼ b1 soluble guanylate cyclase subunit
AchR¼ acetylcholine receptor
ATP¼ adenosine triphosphate
ATP5a¼mitochondrial ATP synthase alpha-subunit
cGMP¼ cyclic guanosine monophosphate
DETANO¼ diethylenetriamine NONOate





GC¼ soluble guanylate cyclase
GC1¼ soluble guanylate cyclase 1 comprising a1 and
b1 guanylate cyclase subunits
GC2¼ soluble guanylate cyclase 2 comprising a2 and
b1 guanylate cyclase subunits




MTCO1¼mitochondrial cytochrome C oxidase 1
MuRF1¼muscle-specific RING finger protein 1
NDUFB8¼NADH dehydrogenase 1 beta subcomplex, 8
NO¼ nitric oxide
nNOS¼ neuronal nitric oxide synthase
PDE5¼ phosphodiesterase 5
PGC1a¼ peroxisome proliferator-activated receptor,
gamma, coactivator 1, alpha
PKG¼ cGMP-activated protein kinase
Quad¼ quadriceps




UQCRC2¼ ubiquinol–cytochrome c reductase core
protein II
VDAC1¼ voltage-dependent anion channel 1
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